Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug 601 shows promise in major trial for blurry vision

NCT ID NCT05520177

Completed Disease control Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called 601 against an existing drug, ranibizumab, for people with vision loss due to a blocked vein in the eye (branch retinal vein occlusion). 351 adults received injections into the eye to reduce swelling and improve sight. The goal was to see if 601 works as well as the standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRANCH RETINAL VEIN OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

branch retinal artery occlusion Macular Edema occlusion of tributary of retinal vein retinal vein occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRANCH RETINAL VEIN OCCLUSION

Contacts and locations

Locations

  • BeiJing Hospital

    Beijing, Beijing Municipality, 100730, China

  • HeNan Provincial Eye Hospital

    Zhengzhou, Henan, 450003, China

  • JiangSu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • ShangHai General Hospital

    Shanghai, Shanghai Municipality, 200080, China

  • The First Affiliated Hospital of JiNan University

    Guangzhou, Guangdong, 510630, China

  • The Second XiangYa Hospital of Central South University

    Changsha, Hunan, 410011, China

  • TianJin Eye Hospital

    Tianjin, Tianjin Municipality, 300020, China

  • TianJin Medical University Eye Hospital

    Tianjin, Tianjin Municipality, 300384, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610000, China

  • ZheJiang Province People's Hospital

    Hangzhou, Zhejiang, 310024, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.